GlobeNewswire Inc | Feb 22, 2021 04:30PM EST

February 22, 2021

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.

Conference Call Information:

Date: Thursday, February 25, 2021Time: 8:30 am Eastern TimeDomestic Dial-in: 877-423-9813International Dial-in: 201-689-8573Conference ID: 13716171Webcast: http://public.viavid.com/index.php?id=143423

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID), anthrax (NasoShield) and influenza (NasoVAX); an intranasal immune modulating therapeutic for COVID-19 (T-COVID); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visitwww.altimmune.com.

Investor & Media Contacts:

Will Brown Stacey JurchisonChief Financial Officer Sr. Dir, Investor RelationsPhone: 240-654-1450 Phone: 410-474-8200wbrown@altimmune.com sjurchison@altimmune.com